Ipilimumab in advanced melanoma: reports of long-lasting responses

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Melanoma research

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CMR.0b013e328353e65cPMID 22516968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contrasting treatment‐specific survival using double‐robust estimators

  2012cited by this paper
• A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

  2010cited by this paper
• Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

  2009cited by this paper
• Immunotherapy of distant metastatic disease

  2009cited by this paper
• Phase I/II trial of tremelimumab in patients with metastatic melanoma.

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Current systemic therapy for metastatic melanoma

  2009cited by this paper
• Small molecules and targeted therapies in distant metastatic disease

  2009cited by this paper
• Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

  2009cited by this paper
• Anti-CTLA-4 therapy in melanoma: Role of ipilimumab (MDX-010)

  2009cited by this paper
• Ipilimumab: controversies in its development, utility and autoimmune adverse events

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

  2009cited by this paper
• The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

  2008cited by this paper
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

  2008cited by this paper
• Current management of metastatic melanoma.

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

  2008cited by this paper
• Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

  2008cited by this paper
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008cited by this paper
• AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.

  2007cited by this paper
• Chemotherapy for metastatic melanoma

  2007cited by this paper
• Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.

  2007cited by this paper
• Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma

  2007cited by this paper
• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  2007cited by this paper
• Toward a molecular classification of melanoma.

  2007cited by this paper
• Costimulation, coinhibition and cancer.

  2007cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Treatments for metastatic melanoma: synthesis of evidence from randomized trials.

  2006cited by this paper
• Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

  2006cited by this paper
• Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Treatment of metastatic malignant melanoma

  2005cited by this paper
• Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

  2005cited by this paper
• Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

  2004cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• Dendritic cell vaccination and immunostimulation in advanced melanoma

  2003cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• Duration of survival for disseminated malignant melanoma: results of a meta-analysis.

  2000cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines

  2025cites this paper
• Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

  2024cites this paper
• Efficiency and Future Significance of CTLA-4 and PD-1 Checkpoints Blockade Immunotherapy

  2023cites this paper
• Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy.

  2023cites this paper
• Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

  2023cites this paper
• Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy

  2022cites this paper
• Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles.

  2022cites this paper
• Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis

  2022cites this paper
• Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

  2022cites this paper
• PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

  2021cites this paper
• Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

  2021cites this paper
• Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy

  2020cites this paper
• The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology

  2020cites this paper
• Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.

  2020cites this paper
• Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma.

  2020cites this paper
• The e cacy and safety of immune checkpoints inhibitors plus radiotherapy as a combination therapy for advanced non-small cell lung carcinoma: a meta- analysis

  2020cites this paper
• Current Perspectives on Nasopharyngeal Carcinoma.

  2019cites this paper
• Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review

  2019cites this paper
• Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro

  2019cites this paper
• Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer

  2019cites this paper
• Anticancer Immunotherapy: Prospects and Challenges

  2019cites this paper
• Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors

  2018cites this paper
• Immune checkpoint blockade opens a new way to cancer immunotherapy

  2018cites this paper
• Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation

  2018cites this paper
• Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy

  2018cites this paper
• Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer

  2018cites this paper
• Preclinical evaluation of immunostimulatory gene therapy for pancreatic cancer

  2017cites this paper
• A perspective on the impact of radiation therapy on the immune rheostat

  2017cites this paper
• Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

  2017cites this paper
• Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

  2017cites this paper
• Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.

  2017cites this paper
• Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.

  2017cites this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  2017cites this paper
• CTLA-4 and PD-1 Pathways

  2016influential citation
• Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma

  2016cites this paper
• Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

  2015cites this paper
• Melanoma versus vitiligo: Clinical aspects and implications for immunotherapy

  2015cites this paper
• Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine

  2015cites this paper
• Therapy Preferences in Melanoma Treatment - Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls

  2014cites this paper
• Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis

  2014cites this paper
• Novel treatment strategies in advanced melanoma: clinical data analysis with regards to registered indications in Poland

  2014cites this paper
• Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

  2014cites this paper
• Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma.

  2014cites this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cites this paper
• Tumor cell lysates as immunogenic sources for cancer vaccine design

  2014cites this paper
• Experimental adenovirus gene therapy for cancer patients with advanced tumors : Translational medicine from basic research to the patient's bedside

  2013cites this paper
• Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

  2013cites this paper
• Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.

  2013cites this paper
• Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options

  2013cites this paper
• Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

  2013cites this paper
• The evolution of S100B inhibitors for the treatment of malignant melanoma.

  2013cites this paper
• Recent developments in the treatment of renal cell carcinoma

  2013cites this paper
• Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice

  2013cites this paper
• Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

  2012cites this paper
• AACR Cancer Progress Report 2012

  2012cites this paper
• Grant/Project/Contract/Support Information

  2012cites this paper